Research

Hormonal

Semaglutide is associated with an increased incidence of neoplasms (cancer) in clinical trials, specifically involving the thyroid, bladder, colorectal, and pancreas, although the absolute number of cases is often low and causality is not conclusive.

If you are taking semaglutide (Ozempic/Wegovy), be aware that clinical trials showed a small number of cancer cases, particularly in the thyroid, bladder, and pancreas. However, the paper notes this is not conclusive proof that the drug causes cancer, as obesity and diabetes themselves increase cancer risk. You should discuss your personal risk factors (especially family history of thyroid cancer) with your doctor.

GoodQualifiesHIGH confidence
Semaglutide is associated with increased neoplasm and tumorigenesis, specifically in the thyroid, bladder, colorectal, and pancreas. Doses of 0.5–1.0 mg yielded 1–155 cases of cancer development in the treatment period of 30–104 weeks.
Shahad Sabaawi Ibrahim et al. · Cancer and Metastasis Reviews · 2024

Why this rating

Based on Phase 3 clinical trial data (Table 4), which is higher quality than the preclinical data for other agonists, though the paper notes the evidence is not conclusive.

Source

The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer

Shahad Sabaawi Ibrahim et al. · Cancer and Metastasis Reviews · 2024

DOI 10.1007/s10555-024-10192-9

narrative_reviewCited 43×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →